Gladman D D, Blake R, Brubacher B, Farewell V T
Rheumatic Disease Unit, University of Toronto, ON, Canada.
J Rheumatol. 1992 Nov;19(11):1724-6.
Our aim was to examine the efficacy of chloroquine in psoriatic arthritis (PsA) and to assess whether chloroquine therapy exacerbated psoriasis. Thirty-two patients had been given chloroquine therapy while attending the University of Toronto Psoriatic Arthritis Clinic. Twenty-four patients continued therapy for at least 6 months, and 18, or 75%, demonstrated > 30% reduction in the actively inflamed joint count. Moreover, there was a significant decrease in the number of actively inflamed joints. A control group, consisting of 24 patients taking no remittive agents, seen during the same period of time, was identified. Only 14, or 58%, of these patients had a > 30% reduction in inflamed joint count over a 6-month period. This pattern was not significantly different (p = 0.19) from the chloroquine treated group. Of the 32 patients who had been given chloroquine, a total of 6 had an exacerbation of psoriasis, only 1 discontinued therapy. There was no case of exfoliative dermatitis. Six of the 24 control patients had an exacerbation of psoriasis. Our experience suggests that chloroquine may be an effective treatment in PsA, and that it does not exacerbate psoriasis. A prospective, randomized, double blind, controlled trial of antimalarial therapy in PsA is warranted.
我们的目的是研究氯喹在银屑病关节炎（PsA）中的疗效，并评估氯喹治疗是否会加重银屑病。32例患者在多伦多大学银屑病关节炎诊所就诊时接受了氯喹治疗。24例患者持续治疗至少6个月，其中18例（75%）炎症活跃关节计数减少超过30%。此外，炎症活跃关节的数量显著减少。确定了一个对照组，由24例在此期间未服用缓解药物的患者组成。这些患者中只有14例（58%）在6个月内炎症关节计数减少超过30%。这种模式与氯喹治疗组无显著差异（p = 0.19）。在接受氯喹治疗的32例患者中，共有6例银屑病加重，只有1例停止治疗。没有剥脱性皮炎病例。24例对照患者中有6例银屑病加重。我们的经验表明，氯喹可能是治疗PsA的有效药物，且不会加重银屑病。有必要对PsA进行抗疟治疗的前瞻性、随机、双盲、对照试验。
